A Study on Intima Media Thickness (IMT) in Middle-aged Subjects (IMT)

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: October 22, 2008
Last updated: January 11, 2010
Last verified: January 2010
This is an observational study to measure the thickness of artery walls in the neck (intima media thickness IMT) by ultrasound examination in middle-aged subjects with central obesity. The purpose of this study is to obtain local data how common asymptomatic atherosclerosis is, and to investigate the association between Cardiovascular Disease risk factors and intima media thickness (IMT) in the Hong Kong population. Results from this study may enhance the public awareness of asymptomatic atherosclerosis and understand its role in the development of Cardiovascular Disease in Hong Kong.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Study on Intima Media Thickness (IMT) in Middle-aged Subjects

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To investigate the prevalence of asymptomatic atherosclerosis by measurement of intima media thickness (IMT) in middle-aged subjects with central obesity in Hong Kong, [ Time Frame: during the one single study visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To examine the association between IMT value and cardiovascular disease (CVD) risk factors, and blood lipid and glucose profiles in middle-aged centrally obese subjects in Hong Kong. [ Time Frame: During the one single study visit ] [ Designated as safety issue: No ]
  • IMT results to be compared with what being reported in the recent literature on normal Chinese population. [ Time Frame: During the one single study visit ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: October 2008
Study Completion Date: June 2009

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
aged 55 or above with central obesity, male more than 90 cm; female more than 80 cm

Inclusion Criteria:

  • Male or female aged 55 years or above.
  • Waist circumference: male more than 90 cm; female more than 80 cm.

Exclusion Criteria:

  • Any known chronic diseases requiring long-term medication such as hypertension, diabetes and hyperlipidemia.
  • Presence of known cardiovascular diseases including cerebro-vascular disease, coronary heart disease and peripheral artery disease.
  • Presence of any active major diseases that may interfere the physical conditions and body weight of subjects during the study period, which include malignancy, infection, renal or liver function impairment, recent major surgery (within 3 months).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00784264

Hong Kong
Research Site
Hong Kong, Hong Kong
Sponsors and Collaborators
Study Director: Karen Yuen AstraZeneca Hong Kong Ltd
Principal Investigator: Chun chung Chow, MD Prince of Wales Hospital, Shatin, Hong Kong
  More Information

Responsible Party: Karen Yuen, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00784264     History of Changes
Other Study ID Numbers: NIS-CHK-DUM-2008/1 
Study First Received: October 22, 2008
Last Updated: January 11, 2010
Health Authority: Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Keywords provided by AstraZeneca:
Asymptomatic atherosclerosis
Intima media thickness (IMT)
central obesity
cardiovascular disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016